Acetazolamide came into medical use in 1952. Acetazolamide, sold under the trade name Diamox among others, is a medication used to treat glaucoma, epilepsy, altitude sickness, periodic paralysis... There has been a lot of research on Acetazolamide on invitro glioblastoma cells.
In July 2018, an interesting study was published about the use of Acetazolamide in mice. Unfortunately, I missed it and now I decided to write about it.
The study showed that repurposing ACZ might be particularly effective in a subgroup of MGMT promoter methylated tumors that have high BCL-3 expression.
ACZ greatly increased the effectiveness of temozolomide in some types of glioblastoma cells. The effectiveness of ACZ depended on its administration schedule. In experiments with mice, a dose of 5 mg / kg ACZ was used, which seems to be achievable in humans.
The most impressive results were in mice with glioblastoma GBM43S (BCL-3 high):
Kaplan-Meier curves of mice bearing intracranial GBM43S PDX (n = 7 per group) treated with TMZ on days 5, 7, and 9 (5 mg/kg
per dose) and/or ACZ on days 5 to 26 (15 mg/kg per day).